Randomized clinical trial to evaluate the effectiveness of enrofloxacin as a second-line antibiotic for treatment of acute Escherichia coli mastitis

Animal Science Journal = Nihon Chikusan Gakkaihō
Yasunori ShinozukaAiko Watanabe

Abstract

The objective of the present study was to evaluate the effectiveness of enrofloxacin (ERFX) as a second-line antibiotic for treatment of acute Escherichia coli (E. coli) mastitis. Forty-two cows with naturally occurring acute E. coli mastitis were enrolled. On the first day of treatment (day 0), empirically selected antibiotics (oxytetracycline: n = 32, kanamycin: n = 10) were administered. Although systemic signs improved in 10 cows (first-line group), the signs remained unchanged or worsened in 32 cows on day 1, including two cows that were found dead. The 30 surviving cows were randomly assigned to second-line groups constituting an ERFX group (n = 19) or a control group (n = 11) that was treated with other antibiotics. Response to each treatment was evaluated by measuring clinical signs from day 0 to day 3, subsequent quarter milk recovery, and the 60-day survival rate. Appetite on day 3 was significantly better in the ERFX group compared to the control group. No significant differences were observed in the 60-day survival rate or the subsequent milk recovery between the ERFX group and the control group. Thus, the use of ERFX as a second-line antibiotic for the treatment of acute E. coli mastitis could induce a rapid appeti...Continue Reading

References

Aug 13, 1997·European Journal of Pharmacology·D HoebenC Burvenich
Oct 17, 2001·Journal of the American Veterinary Medical Association·J R WenzR J Callan
Oct 15, 2003·Veterinary Research·Henri SeegersFrançois Beaudeau
Oct 15, 2003·Veterinary Research·Joe Hogan, K Larry Smith
Oct 15, 2003·Veterinary Research·Christian BurvenichLuc Duchateau
Jul 18, 2006·Journal of the American Veterinary Medical Association·John R WenzGeorge M Barrington
Sep 6, 2007·Journal of Animal Science·X Zhao, P Lacasse
Jun 6, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter CollignonFrank M Aarestrup
May 18, 2013·Journal of Veterinary Pharmacology and Therapeutics·L SuojalaS Pyörälä
Feb 11, 2016·The Journal of Veterinary Medical Science·Yasunori ShinozukaKazuhiro Kawai

❮ Previous
Next ❯

Citations

Feb 27, 2020·The Journal of Veterinary Medical Science·Keiichi HisaedaKazuhiro Kawai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.